News | July 14, 2009

Study Looks at Long-term Outcomes of DES Use in Patients With RI

July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for target vessel revascularization (TVR), these stents appear to be associated with unfavorable long-term outcomes in patients with moderate or severe renal insufficiency (RI), according to a study in this week’s issue of the International Journal of Cardiology, Volume 136, Issue 1, pages 72-79, July 2009.

Researchers at Rui Jin Hospital and Jiao Tong University School of Medicine in Shanghai, China, sought to examine the impact of moderate or severe RI on long-term clinical outcomes after successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation. They found all-cause mortality and major adverse cardiac events were prospectively determined for 1,174 patients after successful PCI with drug-eluting stent implantation. Based on estimated creatinine clearance (CrCl) levels, long-term outcomes were compared between patients with CrCl

Patients in the RI group were older, mainly female and had lower body weights and hemoglobin than those in the control group. The RI group also had fewer cigarette smokers. During follow-up (averaged 19.2 months) after successful PCI, all-cause death (8.3 percent vs. 1.5 percent), cardiac death (5.7 percent vs. 1.1 percent) and occurrence of nonfatal myocardial infarction (2.2 percent vs. 0.4 percent) were significantly higher, but the rate of TVR was lower (5.7 percent vs. 9.6 percent) in the RI group than in the control group. Multivariate analysis revealed that a CrCl

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init